Compare BridgeBio Pharma Inc (BBIO) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Johnson & Johnson — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.36B), while Johnson & Johnson trades at $258.91 (market cap $626.09B). The key difference: Johnson & Johnson is far larger — about 38.3× BridgeBio Pharma Inc's market cap, and Johnson & Johnson pays a 2.06% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | JNJ | |
|---|---|---|
Market Cap | $16.36B | $626.09B |
Sector | Health | Health |
52-Week High | $90.17 | $267.24 |
52-Week Low | $47.29 | $172.78 |
Enterprise Value | $18.14B | $654.37B |
Volume | — | 6,156,228 |
Dividend Yield | — | 2.06% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
